Spots Global Cancer Trial Database for Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma

Study Description

Brief Summary: Primary objective:To assess the efficacy, defined as overall survival, of sequential versus combination chemotherapy for advanced colorectal cancer (CRC). Methodology Open, randomised multicenter phase III study. Randomisation by centre will be centralized. 820 patiënts with histologically proven advanced CRC; not amenable to curative surgery. Measurable or evaluable disease. Age 18 years and above. WHO performance status 0-2. Test products: Arm A: First line: capecitabine capecitabine 1250 mg/m2 orally b.i.d. on day 1-14 (q3),until progression or unacceptable toxicity. Second line: irinotecan 350 mg/m2 IV infusion on day 1 (q3),until progression or unacceptable toxicity. Third line: oxaliplatin 130 mg/m2 IV infusion on day 1 and capecitabine 1000 mg/m2 orally b.i.d. on day 1-14 (q3). Arm B: First line: irinotecan 250 mg/m2 IV infusion in 30 minutes on day 1 and capecitabine 1000 mg/m2 orally b.i.d. on day 1-14 (q3), until progression or unacceptable toxicity. Second line: oxaliplatin 130 mg/m2 IV on day 1 and capecitabine 1000 mg/m2 orally b.i.d. on day 1-14 (q3), until progression or unacceptable toxicity. Patients will be followed by CT-scan every 9 weeks for response while on treatment, or at any other moment when progression is suspected. After cessation of chemotherapy, patients will be followed every 3 months until death. Clinical and laboratory toxicity/symptomatology will be graded according to NCI common criteria.

Detailed Description: Objectives: Primary objective: To assess the efficacy, defined as overall survival, of sequential versus combination chemotherapy for advanced CRC. Secondary objectives are to assess: To assess Tumour response (CR, PR or SD) Progression free survival Quality of life Toxicity profile Methodology Open, randomised multicenter phase III study. Randomisation by centre will be centralized by IKC. Number of patients 820 Main criteria for inclusion Histology and staging disease * Histologically proven advanced CRC; not amenable to curative surgery; * Of Note: In case of a single metastasis, histological or cytological proof of colorectal carcinoma should be obtained prior to randomisation. * Measurable or evaluable disease. Serum CEA as the only parameter for disease activity is not allowed. General conditions * Written informed consent; * Age 18 years and above; * WHO performance status 0-2; * Adequate bone marrow function (WBC \> 3.0 x 109/L, platelets \> 100 x 109/L, Hb \> 6 mmol/L); * Adequate hepatic function: total bilirubin \< 1. 5 x upper normal limit, ASAT and ALAT \< 3 x upper normal limits (in case of liver metastases \< 5 x upper normal limits); * Adequate renal function: creatinin \< 1. 5 x upper normal limits. Other * Expected adequacy of follow-up. Main criteria for exclusion General conditions * Pregnancy or lactation; * Patients (M/F) with reproductive potential not implementing adequate contraceptives measures. Prior or current history * Prior chemotherapy for advanced disease; prior adjuvant chemotherapy is allowed, provided that the last drug administration took place more than 6 months prior to randomisation. * Serious concomitant diseases preventing the safe administration of chemotherapy or likely to interfere with the study assessments; * Serious active infections; * Inflammatory bowel disease or other diseases associated with chronic diarrhoea; * Previous extensive irradiation of pelvis or abdomen; * Other malignancies in the past 5 years with the exception of adequately treated carcinoma in situ of the cervix or squamous or basal cell carcinoma of the skin. Concomitant treatments * Concomitant (or within 4 weeks before randomisation) administration of any other experimental drug under investigation; * Concurrent treatment with any other anti-cancer therapy. Test product, dose and mode of administration Arm A First line: capecitabine Every 3 weeks (q 3): capecitabine 1250 mg/m2 orally b.i.d. on day 1-14. This schedule will be continued until progression or unacceptable toxicity. Continuation after 6 months without disease progression and/or severe toxicity at the investigator's discretion. Second line: irinotecan Every 3 weeks (q 3): irinotecan 350 mg/m2 IV infusion on day 1. This schedule will be continued until progression or unacceptable toxicity. Continuation after 6 months without disease progression and/or severe toxicity at the investigator's discretion. Third line: oxaliplatin plus capecitabine oxaliplatin 130 mg/m2 IV infusion on day 1 and capecitabine 1000 mg/m2 orally b.i.d. on day 1-14. This schedule will be continued until progression or unacceptable toxicity. Continuation after 6 months without disease progression and/or severe toxicity at the investigator's discretion. Arm B First line: irinotecan plus capecitabine Every 3 weeks (q 3): irinotecan 250 mg/m2 IV infusion in 30 minutes on day 1 2 hours after discontinuation of the infusion followed by capecitabine 1000 mg/m2 orally b.i.d. on day 1-14. This schedule will be continued until progression or unacceptable toxicity. Continuation after 6 months without disease progression and/or severe toxicity at the investigator's discretion. Second line: oxaliplatin plus capecitabine Every 3 weeks (q 3): oxaliplatin 130 mg/m2 IV infusion in 2 hours on day 1 and capecitabine 1000 mg/m2 orally b.i.d. on day 1-14. This schedule will be continued until progression or unacceptable toxicity. Continuation after 6 months without disease progression and/or severe toxicity at the investigator's discretion. Duration of treatment and follow-up Treatment is continued until disease progression, or unacceptable toxicity. Patients will be followed by CT-scan every 9 weeks for response while on treatment, or at any other moment when progression is suspected. After cessation of chemotherapy, patients will be followed every 3 months until death. Death or progression should be reported whenever it occurs. Criteria for evaluation Efficacy All patients will be included in the survival analysis (intent-to-treat). All patients receiving \> 9 weeks of treatment (i.e. 3 cycles) will be considered evaluable for response, unless documented progression occurred earlier. Safety profile Safety will be analysed in each treatment group. Patients having received \> treatment doses are evaluable for toxicity. Evaluation will be performed by patient and by cycle on the intent-to-treat population. Clinical and laboratory toxicity/symptomatology will be graded according to NCI common criteria. The adverse events which are not reported in NCI common criteria will be graded as: mild, moderate, severe, life threatening. Statistical methodology The expected median survival in Arm A (standard arm) is 14 months. It is anticipated that the median survival in Arm B (experimental arm) will be 19 months. 620 patients (310 in each arm) are needed to show this increase in median survival (\>=0,05 and \>=0,80). Stratification parameters Patients will be stratified for the following parameters: * WHO performance status 0-1 vs 2 * Serum LDH normal versus above normal * Prior adjuvant therapy versus no prior adjuvant therapy * Predominant localisation of metastases in the liver vs extrahepatic site(s) * Per participating institution

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial